AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

被引：0
|
作者：
Kumar, R. [1 ,2 ]
Kim, S. H. [3 ]
Zhong, D. [4 ]
Lu, S. [5 ]
Cheng, Y. [6 ]
Chen, M. [7 ]
Cho, E. [8 ]
Clay, T. [9 ]
Kang, J. -H. [10 ]
Lee, G. -W. [11 ]
Sun, M. [12 ]
Shim, B. -Y. [13 ]
Spigel, D. R. [14 ]
Yang, T. -Y. [15 ]
Wang, Q. [16 ]
Chang, G. -C. [17 ]
Yu, G. [18 ]
Wang, R. [19 ]
Luo, X. [19 ]
Zheng, H. [20 ]
Gao, R. [19 ]
Kim, H. R. [21 ]
机构：
[1] New Zealand Clin Res, Christchurch, New Zealand
[2] Univ Otago, Dept Pathol, Dunedin, New Zealand
[3] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med,Div Hematol & Med Oncol, Seongnam, South Korea
[4] Tianjin Med Univ, Dept Oncol, Gen Hosp, Tianjin, Peoples R China
[5] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[6] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[7] Zhejiang Univ Canc Hosp, Dept Bioinformat, Coll Life Sci, State Key Lab Plant Physiol & Biochem, Hangzhou, Peoples R China
[8] Gachon Univ, Coll Med, Gil Med Ctr, Incheon, South Korea
[9] St John God Subaico Hosp, Dept Med Oncol, Subiaco, WA, Australia
[10] Catholic Univ Korea, Seoul St Marys Hosp, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea
[11] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Div Hematol & Oncol,Dept Internal Med, Jinju, South Korea
[12] Shandong First Med Univ, Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[13] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Dept Internal Med, Suwon, South Korea
[14] Sarah Cannon Res Inst SCRI, Tennessee Oncol, PLLC, Nashville, TN USA
[15] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[16] Zhengzhou Univ, Henan Canc Hosp, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[17] Chung Shan Med Univ Hosp, Div Pulm Med, Dept Internal Med, Taichung, Taiwan
[18] Weifang Med Univ, Weifang Peoples Hosp, Oncol Dept, Weifang, Peoples R China
[19] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[20] BeiGene USA Inc, San Mateo, CA USA
[21] Yonsei Univ, Dept Internal Med, Yonsei Canc Ctr, Coll Med,Div Med Oncol, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
TIGIT antibody; PD-1; inhibitor; metastatic NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-07
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [1] AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
    Kim, Se Hyun
    Lee, Gyeong-Won
    Shim, Byoung Yong
    Spigel, David R.
    Shiah, Her-Shyong
    Frentzas, Sophia
    Yoon, Harry H.
    Wang, Feng
    Sun, Meili
    Clay, Timothy Dudley
    Zheng, Hao
    Tan, Wei
    Zhou, Ziqi
    Wang, Ruihua
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)
    Sun, M.
    Spigel, D. R.
    Lee, Y-J.
    Yoon, H.
    Liu, Y.
    Ahern, E.
    Harris, S.
    Lee, G-W.
    Yan, D.
    Chen, J.
    Shiah, H-S.
    Deng, T.
    Zheng, H.
    Tan, W.
    Zhou, Z.
    Wang, R.
    Ba, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S862 - S863
  • [3] AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
    Yu, Y.
    Huang, D.
    Gao, B.
    Zhao, J.
    Hu, Y.
    Zhuang, W.
    Kao, S.
    Xu, W.
    Yao, Y.
    Yang, T-Y.
    Lee, Y.
    Kim, J-S.
    Shiah, H-S.
    Wang, R.
    Zheng, H.
    Tan, W.
    Gao, R.
    Kim, H. R.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1019 - S1019
  • [4] AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
    Frentzas, Sophia
    Kao, Steven
    Gao, Rang
    Zheng, Hao
    Rizwan, Ahsan
    Budha, Nageshwar
    Pedroza, Luz de la Hoz
    Tan, Wei
    Meniawy, Tarek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
  • [5] PERIPHERAL PHARMACODYNAMIC (PD) EFFECTS OF OCIPERLIMAB (OCI) IN COMBINATION WITH TISLELIZUMAB (TIS) IN PATIENTS WITH ADVANCED SOLID TUMORS: ADVANTIG-105 PHASE 1 DOSEESCALATION STUDY
    Tan, Wei
    Shi, Yang
    Yan, Han
    Shen, Zhirong
    Budha, Nageshwar
    Rizwan, Ahsan
    Huang, Ruiqi
    Zheng, Hao
    Gao, Rang
    Frentzas, Sophia
    Kao, Steven
    Meniawy, Tarek
    Zhang, Yun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A799 - A799
  • [6] AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
    Frentzas, Sophia
    Meniawy, Tarek
    Kao, Steven Chuan-Hao
    Wang, Ruihua
    Zuo, Yunxia
    Zheng, Hao
    Tan, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses
    Chu, Quincy
    Ciuleanu, Tudor
    Ramlau, Rodryg
    Renouf, Daniel
    Juergens, Rosalyn
    Kalinka, Ewa
    Sawrycki, Piotr
    Bramson, Jonathan
    Nelson, Brad
    Crabbe, Rafael
    Sahlender, Daniela A.
    Crompton, Philippa
    Rouits, Elisabeth
    Spaggiari, Dany
    Brichory, Franck
    Piggott, Luke
    Schenker, Mike
    Goss, Glenwood
    CANCER RESEARCH, 2023, 83 (08)
  • [8] A Phase 1b Dose-Escalation Study of Carotuximab in Combination with Nivolumab in Patients with Metastatic NSCLC
    Robert, F.
    Gray, J. E.
    Trigeiro, A.
    Adams, B.
    Theuer, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S725 - S726
  • [9] A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in Patients with ALK plus NSCLC
    Shaw, Alice
    Loong, Herbert
    Tan, Daniel S. -W.
    Griscti, Kerry
    Gao, Haitao
    Finckenstein, Friedrich
    Scott, Jeffrey
    Vansteenkiste, Johan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S430 - S430
  • [10] Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
    Guo, Ye
    Zhang, Weijie
    Ying, Jieer
    Zhang, Yanqiao
    Pan, Yueyin
    Qiu, Wensheng
    Fan, Qingxia
    Xu, Qi
    Ma, Yue
    Wang, Gang
    Guo, Jing
    Su, Weiguo
    Fan, Songhua
    Tan, Panfeng
    Wang, Yan
    Luo, Yang
    Zhou, Hui
    Li, Jin
    EUROPEAN JOURNAL OF CANCER, 2023, 181 : 26 - 37
12345